Table II.
flTF | asTF | ||||
---|---|---|---|---|---|
Cell lines and tissues | Group | Expression levels | P-value | Expression levels | P-value |
Caco-2 | ApoM OE group | 4.73×10−4±6.22×10−5 | 0.66 | 2.29×10−4±4.53×10−5 | 0.03a |
Control group | 4.23×10−4±9.22×10−5 | 1.19×10−4±1.27×10−5 | |||
EA.hy926 | ApoM OE group | 1.40×10−4±1.43×10−5 | 0.24 | 4.17×10−5±8.43×10−6 | 0.82 |
Control group | 1.59×10−4±3.86×10−6 | 4.50×10−5±1.14×10−5 | |||
HepG2 cells | CDCA group | 4.20×10−4±4.53×10−5 | 0.04a | 1.23×10−4±1.48×10−5 | 0.42 |
Control group | 3.02×10−4±2.34×10−5 | 1.07×10−4±1.11×10−5 | |||
NSCLC | Normal tissues | 0.034±0.034 | 0.97 | 0.005±0.008 | 0.54 |
Adjacent tissues | 0.052±0.067 | 0.011±0.016 | |||
Tumor tissues | 0.040±0.041 | 0.008±0.015 | |||
Cervical cancer | Normal tissues | 0.007±0.006 | 0.62 | 0.0003±0.0004 | 0.001a |
Tumor tissues | 0.007±0.007 | 0.002±0.002 |
Statistically significant difference. ApoM, apolipoprotein M; asTF, alternatively spliced TF; CDCA, chenodeoxycholic acid; flTF, full-length TF; NSCL, non-small cell lung cancer; OE, overexpression; TF, tissue factor.